Learn About Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

What is the definition of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)?
Gastroenteropancreatic neuroendocrine tumor (GEP-NET), also known as carcinoid tumor or islet cell tumor, is a rare disease of cells that control hormones and nerves. Gastroenteropancreatic neuroendocrine tumors most frequently occur in the esophagus, pancreas, stomach, small intestine, colon, rectum, or appendix and can be benign or cancerous. Malignant (cancerous) gastroenteropancreatic neuroendocrine tumors can spread to other parts of the body, such as the lymph nodes, lungs, liver, and bones.
Save information for later
Sign Up
What are the symptoms of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)?
Some individuals with gastroenteropancreatic neuroendocrine tumor may not experience any symptoms. Symptoms of gastroenteropancreatic neuroendocrine tumor may include unexplained weight loss; loss of appetite; nausea; yellowing of the skin, whites of eyes, and mucous membranes (jaundice); facial flushing; and severe diarrhea or gastrointestinal bleeding.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)?
Treatment for a gastroenteropancreatic neuroendocrine tumor that is fast-growing or has spread usually involves surgery to remove the tumor and medications to slow tumor growth, such as octreotide, lanreotide, and telotristat; targeted therapies, such as everolimus and sunitinib; chemotherapy; and peptide receptor radiotherapy (Lu 177 or Lutathera). In individuals with a slow-growing gastroenteropancreatic neuroendocrine tumor, a wait and watch strategy may be followed before deciding on surgery.
Who are the top Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Clinical Trials?
A Cohort Study of Symptom Burden and Therapeutic Selection in Neuroendocrine Tumors (NETs)

Summary: With so many therapeutic options available (i.e.: biologic therapy, liver directed therapy, radiotherapy and chemotherapy), the purpose of this project is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiveness and sequencing of therapy for neuroendocrine tumors (NET) patients. We will conduct a study of a...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Summary: GI tract including pancreas is the one of most common primary sites of neuroendocrine tumors. Current grading of neuroendocrine tumors are based on the 2010 WHO classification. This classifies grade 3 tumors as the neuroendocrine tumor with mitosis > 20 per 10 high power field or Ki-67 labeling index > 20%. Etoposide-based chemotherapy, mostly as the combination with cisplatin, has been the mainst...

What are the Latest Advances for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)?
Resection Prolongs Overall Survival for Nonmetastatic Midgut Small Bowel Neuroendocrine Tumors: A National Cancer Data Base Study.
Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
Tired of the same old research?
Check Latest Advances
Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors.